Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.97M P/E - EPS this Y 46.00% Ern Qtrly Grth -
Income -40.16M Forward P/E -0.74 EPS next Y 7.80% 50D Avg Chg -34.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book 0.58 EPS next 5Y - 52W High Chg -52.00%
Recommedations 1.70 Quick Ratio 2.51 Shares Outstanding 21.41M 52W Low Chg 49.00%
Insider Own 25.00% ROA -68.72% Shares Float 17.61M Beta 0.81
Inst Own 40.82% ROE -136.38% Shares Shorted/Prior 799.87K/442.40K Price 0.94
Gross Margin - Profit Margin - Avg. Volume 87,761 Target Price 9.00
Oper. Margin - Earnings Date May 9 Volume 163,146 Change -7.84%
About Vincerx Pharma, Inc.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Vincerx Pharma, Inc. News
04/09/24 Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
04/09/24 Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
04/08/24 Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
04/01/24 Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/29/24 Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look
03/29/24 Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
03/14/24 12 Most Profitable Biotech Stocks To Invest In
03/05/24 Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/05/24 Vincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past week
01/07/24 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
12/19/23 15 Best Falling Stocks To Buy Now
12/10/23 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
11/14/23 Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/02/23 Vincerx Pharma To Present Three Posters at ASH 2023 in December
10/13/23 New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network
10/06/23 New to The Street Announces TV Corporate Appearances, Broadcasting Episode 518 on Newsmax and Episode 519 on FOX Business Network, Airings start on Saturday, October 7, 2023, at 3:30 PM ET
09/19/23 Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
09/14/23 Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
08/22/23 Vincerx Pharma Announces FDA Clearance of IND for VIP943
08/14/23 10 Oversold Penny Stocks To Buy
VINC Chatroom

User Image precise Posted - 17 hours ago

$VINC https://vincerx.com/BW%20reprint%20041024%20Vincerx.pdf

User Image Lotsofdollars Posted - 17 hours ago

$VINC please dive to the bottom, don't be shy, idiots

User Image P_ether Posted - 19 hours ago

$VINC Chart shows another big drop 🥴🤦‍♂️

User Image P_ether Posted - 19 hours ago

$VINC The problem is… market is not anymore about common sense and logic 🤷🏻‍♂️ Goldman Sachs will puah it wherever it wants…

User Image GPS_OS_21_vs_SOC_5 Posted - 20 hours ago

$VINC In this article published yesterday, She basically says they need to raise cash. 75M shares at .33 - if, if they can get it. https://www.fiercebiotech.com/biotech/aacr-biotechs-emerged-frostbitten-nuclear-winter-ready-show-why-they-fought-survival

User Image arthurkorff Posted - 22 hours ago

$VINC buying 10 shares every penny down till .7

User Image phatmatt511 Posted - 22 hours ago

$VINC let’s go!!

User Image P_ether Posted - 23 hours ago

$VINC 2.57K volume… Looks like they hit few stop losses with dropping it to 81 cents 🤔 Hopefully people are more reasonable now to NOT PUT STOP LOSSES… This is what GOLDMAN SACHS does… They are one of the biggest brokers… THEY SEE YOU!!! THEY SEE YOUR POSITIONS!

User Image ViractaTrader77 Posted - 1 day ago

Looks like war over. Maybe market will pop back. $VINC $STRO

User Image P_ether Posted - 1 day ago

$VINC It is showing me 81 cents here … But all the other platforms showing 90cents 🤔

User Image Jjv7000153 Posted - 1 day ago

$VINC quick question? Alot of people here said vip 152 was to toxic? Why is it still in trials? It's being funded by nih? So was vip 152 no good or it still has a chance?

User Image GPS_OS_21_vs_SOC_5 Posted - 1 day ago

$SLS - Walker Bill aka @telomerase lying on Yahoo about 009 being "just as toxic as other so called cdk9 inhibitors, cured lied again." Pure BullSH The Lowlife Lied about 009 being toxic the morning SLS published Safety Data at ASH confirming 009 Was Safe - No DLT's and No Serious Side Effects at all - not one. If $VINC had published the same data about VIP152/enitociclib, they would still be funding trials and have a mcap of $1B, (VINC was at $700M for a hot minute based solely on there one and only asset at the time, before the tox became evident) Bottom y Screen shot, the pathological liar, lies about lying about 009. $KRON $MAIA $ACHL @SocioCobb @BlackRockBee @FrankWhite2725 @_diagio @Selwot now you know bill is a lowlife - Fact is - The scumbag Knows 009 is worth 10x the whole SLS MCAP

User Image small_gulp Posted - 1 day ago

@precise can you provide a list of inside ownership for me - or share where I can find it. I know the institutional ownership. I spoke to a PHD cancer researcher at Standford, who also presented at AACR 2 weeks ago. I spoke to X for about 45mins about $VINC. Until I reached out and asked for an opinion, X had never heard of Vinc. They're sending me a 2-pager summary in the coming week. But when I asked for a simple quantitively metric - X gave $VINC a 7/10 or 3.5 stars/5 as a company from a purely cancer researchers point of POV - ignoring all financials and other aspects that we care about.

User Image small_gulp Posted - 1 day ago

$VINC

User Image precise Posted - 1 day ago

$VINC My favorite pluck from that article. This crew wants to avoid dilutive financing at all costs. Owning 1/3 of the company will do that. Makes me want to go really big here… Still a good month to mull it over though.

User Image thielindo Posted - 1 day ago

$VINC let's just all go to zero so bears can't stop beating us up

User Image P_ether Posted - 1 day ago

$VINC i can see Goldman Sachs cunts on board… RUN PEOPLE, RUN… This will be in 50s within 2-3 weeks

User Image CC_Abbott Posted - 1 day ago

@precise Thanks, I don't have access to that article either. Regardless, if you take a closer look at $VINC 's slide 13, there are 8 patients [excluding the colon cancer patient in the middle] that fall in the range of SD (<20% increase to <30 reduction) and 1 Partial Response (>30 reduction)

User Image CC_Abbott Posted - 1 day ago

$VINC is included in this news item that covers AACR & biotech https://www.fiercebiotech.com/biotech/aacr-biotechs-emerged-frostbitten-nuclear-winter-ready-show-why-they-fought-survival?utm_medium GL longs!!

User Image MrGuttenburg Posted - 1 day ago

$VINC bringing avg down today. :)

User Image pinguo77 Posted - 1 day ago

$VINC added

User Image phatmatt511 Posted - 1 day ago

$VINC added

User Image P_ether Posted - 1 day ago

$VINC Russell is green 🤷🏻‍♂️🥴🤔

User Image DownWithYou Posted - 1 day ago

$VINC Who bought at $6?

User Image GreenTsunami Posted - 1 day ago

$VINC super volume today, looks like we are digging in for earnings for possible ATM use and June conference for data. Either way, I see this trading flat until then. I hope for the best, and hope all the sellouts get to watch this hit double digits in the summer. Good luck longs!

User Image HuhereChapter11 Posted - 1 day ago

$VINC P&D & a bunch of greedy retail that don't know when to take profits...

User Image telomerase Posted - 1 day ago

$VINC message from VINC IR: "Dear Mr. Bagholder, Thank you for reaching out and for your continued support. I want to assure you that bringing in the capital we need to ensure the continued success of our programs and maximize shareholder value is our highest priority." ------------------------------------------- Wait, is that my car alarm?? HAMDY IS BREAKING INTO MY HONDA FOR MORE CAPITAL. OH THE HUMANITY

User Image telomerase Posted - 1 day ago

$VINC

User Image new_jack Posted - 1 day ago

$VINC all of this.

User Image BioAmerica Posted - 2 days ago

Right now? It depends on how you define favorite. $CRMD (largest position and have already traded to get all my money back). $TGTX (Think is will be BO in next 12 months or so). $VINC (Best trading stock I have. Buy low and sell as it moves up. Building a large paid for position). But remember, I'm not a "buy and hold for a single event" investor. I buy and trade. That is how I limit my risk. I think that is the problem with $AUPH. A lot of these disgruntled longs bought for one event, and when that does not happen, they feel stuck. However, they had plenty of chances to trade this in the past few years, sometimes daily. But they get greedy and miss the sell opportunities along the way.

Analyst Ratings
Cantor Fitzgerald Overweight Apr 9, 24
Cantor Fitzgerald Overweight Apr 1, 24
Cantor Fitzgerald Overweight Sep 7, 23
Chardan Capital Buy Nov 17, 22
SVB Leerink Outperform Aug 12, 22
Cantor Fitzgerald Overweight Jun 8, 22
B. Riley Securities Buy Jun 7, 22
Chardan Capital Buy Jun 7, 22
SVB Leerink Outperform Jun 7, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hamdy Ahmed MD See Remarks See Remarks Aug 09 Buy 0.95 22,300 21,185 96,060 08/10/23
THOMAS TOM C See Remarks See Remarks Aug 10 Buy 0.95 5,000 4,750 219,935 08/10/23
Izumi Raquel E. See Remarks See Remarks Aug 09 Buy 0.92 16,476 15,158 85,214 08/10/23
Izumi Raquel E. See Remarks See Remarks Dec 14 Buy 0.8848 28,738 25,427 68,738 12/14/22
Hamdy Ahmed MD Chief Executive Offi.. Chief Executive Officer Dec 14 Buy 0.8656 35,280 30,538 73,760 12/14/22
THOMAS TOM C See Remarks See Remarks Dec 14 Buy 0.83 7,000 5,810 10,000 12/14/22
Hamdy Ahmed MD Chief Executive Offi.. Chief Executive Officer Jun 23 Buy 1.4106 24,200 34,137 38,480 06/27/22
Bushnell Laura I. Director Director Jun 09 Buy 1.9083 15,000 28,624 19,202 06/13/22